Kiadis raises €23.4m to develop immunotherapy for GVHD

This article was originally published here

Kiadis Pharma has raised €23.4m of funding in a private placement of 2.6 million new shares, for developing a T-cell immunotherapy product to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT).

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply